Date: July 17, 2026 | 03:00 PM - 4:30 PM (IST)
The growing focus on biosimilars and biologics marks a strategic shift from volume-driven generics to high-value innovation-led therapies. The global biosimilars market is witnessing exponential expansion, valued at nearly $39.6 billion in 2025 and projected to exceed $150 billion by 2033.
In India, the biologics market is estimated at around $13.3 billion in 2025 and expected to reach $26.9 billion by 2034, while the biosimilars segment alone is projected to grow from ~$1 billion to over $4 billion in the same period, reflecting strong double-digit growth.
India holds several structural advantages including a well-established generics base, a large pool of scientific talent, competitive manufacturing costs, and a growing ecosystem of biopharma companies. On the regulatory and policy front, revised biosimilar guidelines, faster approval pathways, and increased focus on biopharmaceutical innovation are improving the ecosystem.
However, challenges galore. High capital requirements, complex manufacturing processes, regulatory heterogeneity across markets, and limited domestic innovation funding remain key barriers. Furthermore, India faces intense competition from China, South Korea, and Europe, which benefit from superior infrastructure, higher biologics investments, and faster regulatory approvals.
This webinar explores strategies to accelerate India's position as a global leader in biosimilars and biologics, focusing on market expansion, regulatory advances, and innovation. Industry leaders and stakeholders will discuss actionable strategies to scale production, address regulatory hurdles, and boost global access in the biopharma sector.
Key discussion points:
•India’s transition from volume-led generics to value-driven biologics
•Opportunity in monoclonal antibodies, insulin, oncology, and autoimmune therapies
•Role of Biopharma SHAKTI, PLI scheme and policy support
•Navigating CDSCO and global regulatory pathways: USFDA, EMA, MHRA, WHO among others
•Building capabilities in biologics research, development, and manufacturing
•Strengths in talent pool, cost efficiency, and global supply capabilities
•Addressing high capital requirements and the need for sustained funding
•Strategic roadmap to emerge as a global biologics and biosimilars hub
Date: July 17, 2026
Time: 3 PM to 4:30 PM
Suggested image description:
An Indian scientist working with advanced biologics tools (cell culture, microscopy, analytics), emphasizing talent and R&D strength.
OR
A high-tech biopharma production setup showing bioreactors, cleanroom environment, scientists in PPE, highlighting complexity and scale of biologics manufacturing.
Entry to the e-conference is extended only to professionals based on merit, please submit your registration form to apply for complimentary registration.